Adjuvant Treatment and Follow Up of Differentiated Thyroid Cancer

  • Barbara Jarząb
  • Daria Handkiewicz-Junak
Part of the Head and Neck Cancer Clinics book series (HNCC)


This chapter first reviews briefly how to assess patient prognosis after completion of surgery and thereafter how to tailor medical treatment and follow up.


Thyroid Cancer Papillary Thyroid Cancer Differentiate Thyroid Cancer Thyroid Remnant Neck Ultrasound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. Biermann M, Pixberg M, Riemann B, et al. [Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer—results after 874 patient-years of follow-up in the MSDS-trial.] Nuklearmedizin 2009;48:89–98.PubMedGoogle Scholar
  2. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214.CrossRefPubMedGoogle Scholar
  3. David A, Blotta A, Bondanelli M, et al. Serum thyroglobulin concentrations and 131I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 2001;42:1470–5.PubMedGoogle Scholar
  4. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000;52:765–73.CrossRefGoogle Scholar
  5. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–9.CrossRefPubMedGoogle Scholar
  6. Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61–74.CrossRefGoogle Scholar
  7. Glanzmann C, Lutolf UM. Long-term follow-up of 92 patients with locally advanced follicular or papillary thyroid cancer after combined treatment. Strahlenther Onkol 1992;168:260–9.PubMedGoogle Scholar
  8. Gottlieb JA, Hill CS, Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974;290:193–7.CrossRefPubMedGoogle Scholar
  9. Hackshaw A, Harmer C, Mallick U, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007;92:28–38.CrossRefPubMedGoogle Scholar
  10. Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: A single-center, 53-patient phase 2 study. Thyroid Res 2009;2:8.PubMedCentralCrossRefPubMedGoogle Scholar
  11. Handkiewicz-Junak D, Wloch J, Roskosz J, et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 2007;48:879–88.CrossRefPubMedGoogle Scholar
  12. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol 2010;322:8–28.CrossRefPubMedGoogle Scholar
  13. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877–85.PubMedGoogle Scholar
  14. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy. J Nucl Med 2001;42:1464–9.PubMedGoogle Scholar
  15. Hindie E, Melliere D, Lange F, et al. Functioning pulmonary metastases of thyroid cancer: Does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003;30:974–81.CrossRefPubMedGoogle Scholar
  16. Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:2610–15.CrossRefPubMedGoogle Scholar
  17. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229–42.CrossRefPubMedGoogle Scholar
  18. Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94:1310–16.CrossRefPubMedGoogle Scholar
  19. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941–59.CrossRefPubMedGoogle Scholar
  20. Maxon HR III, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med 1992;33:1132–6.PubMedGoogle Scholar
  21. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447–63.CrossRefPubMedGoogle Scholar
  22. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433–41.CrossRefPubMedGoogle Scholar
  23. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554–64.CrossRefPubMedGoogle Scholar
  24. O’Connell ME, Flower MA, Hinton PJ, et al. Radiation dose assessment in radioiodine therapy. Dose–response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993;28:16–26.CrossRefPubMedGoogle Scholar
  25. Pacini F, Schlumberger M, Dralle H, et al. European Consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.CrossRefPubMedGoogle Scholar
  26. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063–8.CrossRefPubMedGoogle Scholar
  27. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318–23.PubMedGoogle Scholar
  28. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: A surgical perspective. Cancer Treat Rev 2005;31:423–38.CrossRefPubMedGoogle Scholar
  29. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668–76.CrossRefPubMedGoogle Scholar
  30. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009;94:1493–9.CrossRefPubMedGoogle Scholar
  31. Spencer CA, Bergoglio LM, Kazarosyan M, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566–75.CrossRefPubMedGoogle Scholar
  32. Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 2010;95:230–7.CrossRefPubMedGoogle Scholar
  33. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: Role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402–7.CrossRefPubMedGoogle Scholar
  34. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764–70.CrossRefPubMedGoogle Scholar
  35. Verburg FA, Mader U, Luster M, et al. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. Eur J Endocrinol 2009;160:619–24.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  1. 1.Department of Nuclear Medicine and Endocrine OncologyMaria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice BranchGliwicePoland

Personalised recommendations